首页 | 本学科首页   官方微博 | 高级检索  
     


Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer
Authors:Alain Borgeat  Oliver Wilder-Smith  Michel Forni  Peter M. Suter
Affiliation:1. Department of Anesthesiology, University Hospital, CH-1211, Genève 14
2. Departments of Gynecology & Obstetrics, University Hospital of Geneva, Switzerland
Abstract:We investigated the prophylactic antiemetic effect of added lowdose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer. In a prospective open longitudinal study, 117 patients who had more than five episodes of nausea and vomiting in their first chemotherapy cycle during the first 24 hr completed the study. They received in addition to the usual prophylactic antiemetic regimen a continuous intravenous infusion of 1 mg · kg?1 · hr?1 propofol started four hours before chemotherapy and continued up to 24 hr for the two subsequent cycles. The number of vomiting / nausea episodes, level of sedation, patient activity, appetite and preference for future chemotherapy cycles were assessed. In the propofol supplemented cycles 90 and 80% of patients, during the 1st and 2nd propofol-assisted cycle respectively, were free of nausea and vomiting during the first 24 hr after chemotherapy. Patients were more frequently active and had more appetite during the propofol-assisted cycles. No propofol-associated side effects were observed. We conclude that the addition of a subhypnotic infusion of propofol enables better control of nausea and vomiting caused by non-cisplatin chemotherapy in the first 24 hr post-treatment.
Keywords:  font-variant:small-caps"  >anaesthetics, intravenous: propofol     font-variant:small-caps"  >complications: vomiting     font-variant:small-caps"  >vomiting: antiemetics, nausea
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号